Official Title
Synthetic CBD Oil Droplets as a Therapy for Mild to Moderate SARS-CoV-2 Infection. Assesment of Efficacy and Safety.
Brief Summary

The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compared to placebo.

Status
Recruiting
Conditions
COVID19
CBD
Interventions

Drug: CBD

CBD oil not containing THC, to be administered sub-lingual.

Drug: Placebo

Placebo Oil

Eligibility Criteria

Inclusion Criteria:

- COVID 19 patients

- 18 Years and older

Exclusion Criteria:

- Respiratory failure requiring mechanical ventilation

- Intensive care unit admission

- Neutrophile con. < 1000 cells/mm3

- Lymphocyte con < 500 cells/mm3

- Liver enzymes 5 times higher then the norm

- QT interval longer then 500 ms.

- Pregnancy

- Hemodialysis renal replacement therapy

- Active or prior psychotic event

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Israel
Locations

Sheba Medical Center, Tel Hashomer
Ramat Gan, Tel Aviv, Israel

Investigator: Howard Amital, MD, MHA
Contact: +972-3-5302638
Howard.amital@sheba.health.gov.il

Contacts

Howard Amital, MD, MHA
+972-3-5302638
Howard.Amital@sheba.health.gov.il

Investigators

Howard Amital, MD, MHA, Principal Investigator
Head of Internal Medicine ward "B", Sheba Health Center, Tel Hashomer

Sponsors / Collaborators
Sheba Medical Center
NCT Number
NCT04686539
MeSH Terms
COVID-19